This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chan, T M Articles by Lai, K N Search for Related Content PubMed PubMed Citation Articles by Chan, T M Articles by Lai, K N Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AZATHIOPRINE CYCLOPHOSPHAMIDE PREDNISONE Social Bookmarking                         What's this?

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

Division of Nephrology, Department of Medicine: Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong, China.

F K Li

W K Hao

Division of Nephrology, Department of Medicine

K W Chan

Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

S L Lui

S Tang

K N Lai

Division of Nephrology, Department of Medicine

The optimal therapy for pure membranous lupus nephritis (MLN) with nephrotic syndrome remains controversial. While the risk of progressive renal deterioration may be small, persistent heavy proteinuria leads to the complications of oedema, hypoalbuminaemia, hyperlipidaemia, hypercoagulability, and venous thrombosis. We examined prospectively the efficacy and tolerability of a sequential immunosuppressive regimen in a cohort of 20 patients with nephrotic syndrome due to pure MLN (WHO Class Va and Vb). Initial therapy comprised prednisolone (0.8 mg/kg/d p.o.) and cyclophosphamide (2–2.5 mg/kg/d p.o.). Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p.o.) as maintenance therapy. Within 12 months of therapy 11(55%) patients had complete remission (CR), 7(35%) patients achieved partial remission (PR) (proteinuria reduced from 6.2 4.0 to 2.0 1.7 g =24 h, P < 0.01), and 2 patients failed to respond. Improvements in proteinuria and serum albumin level were observed after 3–6 months of treatment. Non-responders had lower baseline serum albumin compared to complete responders. Renal function remained stable during follow-up for 73.5 48.9 months. 8 patients had disease relapse at 47 15 months. Early complications (12 months) included herpes zoster (40%), minor respiratory or urinary tract infections (25%), mild leukopenia (15%), and transient amenorrhea (14.3%). 4 of the 20 patients developed pulmonary tuberculosis during follow-up, at 35 24 months after the diagnosis of MLN. 8 patients had hyperlipidaemia. Haemorrhagic cystitis, permanent amenorrhea, vascular complications, and mortality were not observed. We conclude that this sequential immunosuppressive regimen is effective in 90% of patients with MLN and heavy proteinuria. Prudent consideration of the benefits and potential side-effects is required to determine the optimal management for individual patients.

Key Words: azathioprine • cyclophosphamide • membranous lupus nephritis • nephrotic syndrome

Lupus, Vol. 8, No. 7, 545-551 (1999)
DOI: 10.1191/096120399678840837


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy J. Am. Soc. Nephrol., April 1, 2009; 20(4): 901 - 911. [Abstract] [Full Text] [PDF]

				G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]

				C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, K.-M. Chow, W. Gang, and P. K.-T. Li Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis Rheumatology, November 1, 2008; 47(11): 1678 - 1681. [Abstract] [Full Text] [PDF]

				K C Tse, M F Lam, S C. Tang, C S. Tang, and T M Chan A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade Lupus, January 1, 2007; 16(1): 46 - 51. [Abstract] [PDF]

				F. B. Karassa, J. P. Killen, E. M. Ginzler, M. A. Dooley, and M. Y. Kim Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis. N. Engl. J. Med., February 16, 2006; 354(7): 764 - 765. [Full Text] [PDF]

				H A Austin and G G Illei Membranous lupus nephritis Lupus, January 1, 2005; 14(1): 65 - 71. [Abstract] [PDF]

				L. Mercadal, S. T. d. Montcel, D. Nochy, G. Queffeulou, J.-C. Piette, C. Isnard-Bagnis, and F. Martinez Factors affecting outcome and prognosis in membranous lupus nephropathy Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1771 - 1778. [Abstract] [Full Text] [PDF]

				M Abu-Shakra and Y Shoenfeld xAzathioprine therapy for patients with systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 152 - 153. [Abstract] [PDF]